Normobaric oxygen therapy was shown to be effective in reducing post craniotomy pneumocephalus. Theoretical assessment of normobaric oxygen therapy in treating pneumocephalus has shown that a higher level of oxygen concentration will significantly decrease the time for absorption of pneumocephalus. The therapeutic efficacy is not fully established in patients with chronic subdural hematoma after burr hole drainage. Both radiological outcomes and clinical outcomes would be evaluated.
Chronic subdural hematoma (CSDH) is not a benign disease. Morbidity and mortalities were high especially in those with recurrence requiring reoperations. The use of subdural drain after burr hole drainage is an excellent example demonstrating that by reducing CSDH recurrence, a significant improvement in functional outcomes can be observed. Pneumocephalus is very common after burr hole drainage for CSDH. The use of high-flow oxygen had been reported to be effective in small case series, showing effectiveness in clinical and radiological outcomes. However, no large, prospective, controlled trial has been conducted to establish the efficacy of oxygen therapy on functional outcomes for patients with pneumocephalus after burr hole drainage in CSDH. Bilateral CSDH has a different prognosis and is associated with a poorer outcome. In addition to treating pneumocephalus, the use of perioperative oxygen has been suggested to minimize tissue hypoxemia and infection. In a study published in the New England Journal of Medicine, the use of perioperative supplementary oxygen was shown to reduce surgical site infection. Hyperoxia with oxygen therapy has shown to be safe with minimal changes to the cerebral blood flow (CBF) from functional magnetic resonance imaging (fMRI). Research Questions 1. Does post-operative high-flow oxygen improve pneumocephalus in terms of volume reduction in CSDH patients after burr-hole drainage? 2. Does post-operative high-flow oxygen reduce the recurrence rate of CSDH (radiologically) if pneumocephalus volume is reduced after oxygen therapy? 3. Does post-operative high-flow oxygen reduce the recurrence rate of CSDH (clinically), as defined by symptomatic recurrence requiring reoperation, if pneumocephalus volume is reduced after oxygen therapy? 4. Does post-operative high-flow oxygen improve CSDH patients' functional outcome in terms of modified Rankin Scale (mRS) at 3 months and 6 months? Hypothesis Oxygen therapy for CSDH patients with post-operative pneumocephalus will experience significant resorption of intracranial air within 24 hours. There is a reduction in recurrence rate in terms of the re-operation rates. There is an improvement in functional outcome in terms of mRS. Aim of the Study To evaluate changes in pneumocephalus volume and functional outcome after oxygen therapy in post-operative CSDH patients treated by burr hole drainage, as compared to the standard care by breathing in room air or low concentration oxygen during the post-operative period. Study Design Prospective randomized 1:1 parallel-arm study Methods and Randomization Patients will be recruited when they are considered fit for oxygen therapy as determined by the treating clinician. The timing of burr hole evacuation may vary according to the availability of the emergency operative time slot. The index intervention is postoperative oxygen therapy: 100% normobaric oxygen through a nonrebreather mask (NRM) at 12-15 Litre/minute consecutively for 24 hours. Removal of the nonrebreather mask is allowed during meals or other activities such as physiotherapy. The duration of mask removal would be documented. Compliance with NRM is considered to be good if the mask is kept \> 90% of the time during the 24 hours treatment period. The reference intervention is standard post-operative care: the patient would be breathing in normobaric room air. For the reference arm, if the patient has desaturation (i.e. SaO2 \< 93%), supplemental O2 therapy can be given to keep SaO2 \> 93%. Arterial blood gas would be obtained by the clinicians when deemed necessary. If there is a significant deviation from the study protocol occurs, the patients will be analyzed according to their originally assigned groups (intention-to-treat principle). Non-rebreather masks, when they are tightly applied, are associated with a lower aerosol dispersion distance (as compared to non-invasive positive pressure ventilation or venturi masks). Interim data analysis would be performed and the study would be terminated if a significant difference in the primary outcome is observed.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
36
FiO2 \>80% Oxygen (Delivered with 12-15L/min Non-rebreather Mask)
FiO2 \<30% Oxygen (Delivered with 0-2L/min Nasal Cannula)
Division of Neurosurgery, Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong
Hong Kong, Hong Kong
RECRUITINGChanges in the volume of pneumocephalus after 24 hours of oxygen therapy
Volumetric measurement of pneumocephalus from Computed Tomographic (CT) scan for the Head
Time frame: 24 hours
Modified Rankins Scale (mRS)
Functional outcomes
Time frame: at baseline before admission, on admission, at 1 month, at 3 months and at 6 months.
EuroQOL EQ-5D
Functional outcomes
Time frame: at 1 month, at 3 months and at 6 months.
Glasgow Coma Scale (GCS)
Neurological examination
Time frame: On admission, at 1 month, at 3 months and at 6 months.
Recurrence rate, as defined by reoperation rate due to symptomatic recurrence
Surgical complications
Time frame: Reoperation rate within six months, including the number of re-operations for CSDH during the same admission episode, as well as subsequent readmission for reoperation for CSDH.
Changes in brain volume re-expansion
Volumetric measurement from Computed Tomographic (CT) scan for the Head
Time frame: after 24 hours of oxygen therapy and 1 week after oxygen therapy
Changes in volume of subdural fluid
Volumetric measurement from Computed Tomographic (CT) scan for the Head
Time frame: Recurrence or re-accumulation rate, as measured by an increase in subdural fluid volume at 1 week, 1 month, 3 months, and at 6 months.
Incidence of superficial wound infection
Surgical complications
Time frame: Any surgically associated would infections within 6 months from the index operation
Incidence of deep wound infection, including subdural empyema
Surgical complications
Time frame: Any surgically associated would infections within 6 months from the index operation
Incidence of chest complications, including chest infection
Complications
Time frame: Any complications within the same admission episode for the index operation
Any complications arising from the Oxygen therapy (Adverse events)
Complications
Time frame: Any complications within the same admission episode for the index operation
Barthel Index
Functional outcome
Time frame: at 1 month, 3 months and 6 months
PaO2 and PaCO2 from the arterial blood gas (ABG)
Blood taking for ABG when judged to be necessary by the treating physician or when there is desaturation to SaO2 \< 93%
Time frame: During oxygen therapy
Duration of stay at the acute neurosurgical ward (LOS)
LOS
Time frame: During the same admission episode for the index operation
Discharge destination
Outcome
Time frame: Upon the same admission episode for the index operation
The length of stay in secondary care
LOS
Time frame: Upon transferal to the secondary care from the same admission episode for the index operation
Mortality rate at 30 days, 3 months and 6 months.
Death rate
Time frame: at 30 days, 3 months and 6 months.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.